Table 4.

Treatment-emergent adverse events, regardless of relationship to carfilzomib treatment, reported in 20% of patients or more or related to carfilzomib occurring in 5% of patients or more

Dose escalation (N = 37)Dose expansion (N = 11)
Adverse eventAll grades, n (%)≥ grade III, n (%)All grades, n (%)≥ grade III, n (%)
All causeRelatedAll causeRelatedAll causeRelatedAll causeRelated
Any37 (100)32 (87)26 (70)13 (35)11 (100)10 (91)9 (82)4 (36)
Hematologic events
 Anemia17 (46)5 (14)10 (27)4 (11)8 (73)7 (64)5 (45)4 (36)
 Thrombocytopenia12 (32)4 (11)10 (27)4 (11)7 (64)6 (55)4 (36)3 (27)
 Neutropenia4 (11)1 (3)2 (5)1 (3)3 (27)3 (27)1 (9)1 (9)
 Leukopenia1 (3)1 (3)1 (3)1 (3)2 (18)2 (18)
Nonhematologic events
 Nausea22 (59)14 (38)1 (3)3 (27)3 (27)
 Fatigue19 (51)11 (30)4 (11)2 (5)5 (45)5 (45)
 Constipation16 (43)4 (11)2 (18)1 (9)
 Pyrexia15 (41)9 (24)3 (27)
 Cough14 (38)5 (14)4 (36)
 Vomiting13 (35)9 (24)1 (9)1 (9)
 Anorexia12 (32)5 (14)1 (9)1 (9)
 Diarrhea12 (32)7 (19)3 (8)5 (45)2 (18)
 Dyspnea12 (32)2 (5)1 (3)2 (18)1 (9)
 Headache11 (30)3 (8)2 (18)2 (18)
 Upper respiratory tract infection10 (27)4 (11)2 (18)
 Increased serum creatinine9 (24)5 (14)1 (3)3 (27)3 (27)
 Hyperglycemia8 (22)1 (3)2 (18)1 (9)
 Shoulder pain8 (22)
 Chills7 (19)6 (16)2 (18)1 (9)
 Insomnia7 (19)3 (8)4 (36)1 (9)
 Peripheral edema7 (19)1 (3)3 (27)1 (9)
 Peripheral neuropathy6 (16)5 (14)1 (9)
 Pharyngolaryngeal pain6 (16)4 (11)2 (18)
 Hyperkalemia3 (27)2 (18)1 (9)
 Hypoalbuminemia1 (3)3 (27)3 (27)